First Patient Dosed in TARGET-D 201 Ph 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Metastatic Pancreatic Cancer
“Dosing the first patient in the TARGET-D 201 trial marks an important milestone in the development of VS-7375 for patients with KRAS G12D-mutated metastatic pancreatic cancer, where unmet need remains high,” said Michael Kauffman, M.D., Ph.D., president of development at Verastem Oncology. “We believe VS-7375 has a differentiated profile, including potent KRAS G12D target inhibition and sustained target coverage, supporting its potential to play a significant role in treating multiple KRAS G12D-mutated tumor types. With three registration-directed Phase 2 clinical trials now underway across pancreatic, non-small cell lung, and colorectal cancers, and FDA Fast Track designations in pancreatic and non-small cell lung cancers, we are focused on accelerating development of VS-7375 as quickly as possible across multiple tumor types where no approved treatments exist.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines